OncoMatch/Clinical Trials/NCT06673017
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Is NCT06673017 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PTM-101 for pancreatic ductal adenocarcinoma.
Treatment: PTM-101 — This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No prior chemo-, radio-, or surgical therapy for PDAC
Cannot have received: radiation therapy
No prior chemo-, radio-, or surgical therapy for PDAC
Cannot have received: surgery
No prior chemo-, radio-, or surgical therapy for PDAC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
- Karmanos Cancer Institute · Detroit, Michigan
- Northwell Health Zuckerberg Cancer Center · Lake Success, New York
- University of Texas Southwestern Medical Center · Dallas, Texas
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify